The K-Ras­(G12D) mutation occurs in 27% of pancreatic,10% of colon,and 4% of lung adenocarcinoma patients.−,  New chemical matter hasemerged to explore the noncovalent engagement with the S-IIP or the neo-protein–protein interface betweenRas and cyclophilin A., These compounds with K-Ras­(G12D),pan-K-Ras, or pan-Ras selectivity have entered clinical trials anddemonstrated promising results. This evidence concerns the gene KRAS and lung adenocarcinoma.